TAURIGA SCIENCES INC - TAUG STOCK NEWS

Tauriga Sciences, Inc. (TAUG) has recently filed an additional U.S. Provisional Patent Application for alternative pharmaceutical cannabinoid delivery systems. This complements the conversion of a prior U.S. Provisional Patent to a Non-Provisional Patent Application regarding its pharmaceutical cannabinoid chewing gum, aimed at treating nausea from chemotherapy. The company is making significant strides in its pharmaceutical development initiatives and anticipates updates on clinical trials soon. Tauriga also produces a variety of CBD and CBG infused chewing gums under the Tauri-Gum brand.

Tauriga Sciences, Inc. (OTCQB: TAUG) has entered a 6-month agreement with Coalition Technologies to improve its SEO metrics. The aim is to enhance brand awareness of Tauri-Gum™ and boost e-commerce sales. With a positive industry outlook, the company plans to allocate part of its marketing budget to SEO efforts. Additionally, the recent increase in CBD & CBG infusion concentrations (25mg per piece) is expected to attract more e-commerce customers. Tauriga is also engaged in pharmaceutical development for a medicated version of Tauri-Gum™.

Tauriga Sciences, Inc. (OTCQB: TAUG) has announced the development of a Delta-8-THC infused version of its Tauri-Gum™. This new product will adhere to federal regulations, containing less than 0.3% THC, derived from Industrial Hemp. The company aims to expand its product offerings and revenue streams, focusing on compliance and innovation. The current product line includes CBD and CBG infused chewing gums in various flavors, and the company is engaged in pharmaceutical development for nausea regulation, particularly for chemotherapy patients. Updates for shareholders will be provided in the future.

Tauriga Sciences, Inc. (OTCQB: TAUG) has assembled a new sales force targeting seven U.S. cities: Nashville, Miami, Atlanta, New York City, Minneapolis, Los Angeles, and Houston. This strategic move coincides with the launch of their enhanced Tauri-Gum™ CBD & CBG concentrations (25mg/serving). The company anticipates maintaining MSRP due to reduced production costs. Tauriga focuses on expanding its market share in the U.S. retail sector while complementing its growing E-Commerce operations.

Tauriga Sciences (OTCQB: TAUG) announced the full repayment and retirement of its final convertible debenture valued at $210,000, enhancing its financial position. This milestone comes as the company celebrates the two-year anniversary of its Tauri-Gum product line, which includes CBD and CBG infused chewing gums. CEO Seth M. Shaw highlighted this achievement as an indicator of the company's progress and its commitment to building shareholder value through diverse product offerings and a focus on pharmaceutical development.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced the completion of its largest Tauri-Gum™ production run, investing $267,500 to manufacture 70,000 – 72,000 blister packs across 8 distinct flavors. Each piece of gum contains 25mg of CBD or CBG. The product line is Kosher and Halal certified, vegan, and made in the USA, catering to the growing CBD and CBG edibles market. The company also has a pharmaceutical development initiative aimed at creating a medication-grade version of Tauri-Gum™ for chemotherapy patients.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced a manufacturing partnership with First Foods Group, Inc. to produce a new line of CBD-infused chocolate products. This full spectrum CBD product line, containing 600mg of CBD per unit, includes three diabetic-friendly options incorporating healthful ingredients like melatonin and turmeric. CEO Seth M. Shaw emphasized the company’s focus on quality assurance and long-term growth through product line expansion. Tauriga continues to thrive in the CBD and CBG markets, driven by its innovative offerings and strategic partnerships.

Tauriga Sciences, Inc. (OTCQB: TAUG) has acquired an equity stake in an Israeli biotechnology firm specializing in cannabinoid-based drugs. This strategic acquisition aims to complement Tauriga's ongoing pharmaceutical development efforts involving cannabinoids. The firm plans to file a Form 8-K to provide further details about the acquisition shortly. Currently, Tauriga is known for its Tauri-Gum™ product line, which includes CBD and CBG infused chewing gums, and it is focused on expanding its pharmaceutical initiatives, especially regarding nausea regulation for chemotherapy patients.

Tauriga Sciences, Inc. (TAUG) has launched its 8th Tauri-Gum SKU—Golden Raspberry Flavor infused with 50 µg of Vitamin D3. The company now offers 3 Cannabinoid-Free SKUs alongside its 5 CBD & CBG infused variants. Furthermore, CBD and CBG infusion concentrations have been increased to 25 mg per piece, with a production budget of $267,750. The company is witnessing growth in its E-Commerce segment, having received its 5,515th order.